You are hereMarch 12, 2018
What’s the Stem Cells Buzz this Week? - MPCs and Atherosclerosis, Adhesive Interactions of MSCs, Neuroprotection by PSC-MSCs, Perspective on Diabetic Stroke Therapy!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Mesodermal Progenitor Cells in Atherosclerosis
A recent STEM CELLS study from the lab of Hyo-Soo Kim (Seoul National University Hospital, Korea) aimed to investigate the link between mesodermal progenitor cells (MPC) from the adult bone marrow and atherosclerosis, the buildup of plaque inside your arteries. Cho et al. discovered that Lin‐CD29+Sca‐1+/PDGFRα‐ MPCs with tripotent differentiation capacity mobilized into the peripheral blood and infiltrated the artery under the influence of atherosclerosis-related cytokines. However, the atherosclerotic milieu does not affect Lin‐CD29+Sca‐1+/PDGFRα+ unipotential MPCs. Sounds like a fascinating study!
Adhesive Interactions of MSCs in Flowing Blood
The adhesive nature of mesenchymal stem cells (MSCs) represents one potentially overlooked parameter affecting their infusion as a therapeutic intervention. New research from Gerard B. Nash (University of Birmingham, UK) now establishes that the adhesive behavior of flowing MSC and their ability to stick to surfaces depends on their origin, as this influences how they interact with the platelets in the blood. Sherrif et al. suggest that their findings may have significant implications for therapeutic infusions of MSC, so head on over to STEM CELLS now to read more!
PSC-MSCs Are More Neuroprotective than Fetal MSCs
The therapeutic potential of mesenchymal stem cells (MSCs) relies on the secretion of paracrine acting factors, and new research from Kate E. Hawkins and Pascale V. Guillot (UCL, UK) sought to compare MSCs derived from different sources. Interestingly, their new STEM CELLS Translational Medicine study suggests that MSCs differentiated from pluripotent stem cells (PSC-MSCs) secrete factors that provide greater neuroprotection in the hypoxic-ischemic mouse brain when compared to MSCs from a fetal source (amniotic fluid). Overall, this new study highlights PSC-MSCs as a therapeutically relevant treatment for a range of indications.
Cell-Based and Exosome Therapy in Diabetic Stroke
Patients with diabetes mellitus who suffer a stroke have worse neurological outcomes and long-term functional recovery than non-diabetic stroke patients. To foster further discussions and encourage new therapeutic developments, Jieli Chen (Henry Ford Hospital, Detroit, Michigan, USA) brings us a Perspective article that summarizes current knowledge and highlights promising cell-based and exosome therapy for diabetic stroke. Head over to STEM CELLS Translational Medicine now for a fascinating read.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!